2022
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022, 140: 419-437. PMID: 34758074, PMCID: PMC9353153, DOI: 10.1182/blood.2021012057.Peer-Reviewed Original ResearchConceptsPrimary cutaneous lymphomasNon-Hodgkin lymphomaCutaneous lymphomasMycosis fungoides/Sézary syndromeCutaneous Lymphoma Task ForceInvestigator-initiated trialPotential prognostic factorsNumber of patientsClinical trial guidelinesClinical trial designExtracutaneous diseaseSézary syndromePrognostic factorsTreatment of cancerTrials guidelinesClinical trialsComparative efficacyTrial designNumber of subtypesEuropean OrganizationNew treatmentsLymphomaResponse criteriaTherapeutic agentsStudy design
2021
Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma
Witzig T, Sokol L, Kim W, de la Cruz Vicente F, Caballero D, Advani R, de Oña R, Niebla A, Terol M, Eva D, Bendris N, Ahsan J, Leoni M, Foss F. Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood 2021, 138: 621. DOI: 10.1182/blood-2021-147279.Peer-Reviewed Original ResearchAngioimmunoblastic T-cell lymphomaProgression-free survivalOverall response rateT-cell lymphomaOverall survivalPeripheral T-cell lymphomaT-cell non-Hodgkin lymphomaOpen-label trialPhase 2 studyNegative prognostic factorDuration of responsePotential predictive biomarkersNon-Hodgkin lymphomaT-cell homingProgression of diseasePTCL patientsRefractory PTCLUnacceptable toxicityAdult patientsPrognostic factorsPredictive biomarkersLugano classificationCXCL12 expressionReceptor CXCR4New therapies
2005
Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors
Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, Chan G, Stiffler K, Miller KB. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplantation 2005, 35: 1187-1193. PMID: 15852025, DOI: 10.1038/sj.bmt.1704984.Peer-Reviewed Original ResearchConceptsExtracorporeal photophoresisChronic graftHost diseaseSteroid-refractory chronic graftExtensive chronic graftHigh-risk patientsDe novo onsetUnfavorable risk groupCutaneous GVHDImmunosuppressive medicationsStable diseaseSteroid sparingOral ulcerationExtracorporeal photopheresisMedian durationNovo onsetProspective trialPrognostic factorsPrognostic scoreMedian timeProspective studyRisk groupsPatientsResponse rateProgressive onset
2004
Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome
Foss FM. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. Best Practice & Research Clinical Haematology 2004, 17: 573-584. PMID: 15494295, DOI: 10.1016/j.beha.2004.08.009.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeAnti-vascular endothelial growth factorChemotherapeutic agentsAllogeneic bone marrow transplantationReceptor tyrosine kinase inhibitorsGrowth factorTransplant conditioning regimensBone marrow transplantationTyrosine kinase inhibitorsClonal hematopoietic disordersEndothelial growth factorNovel chemotherapeutic agentsMatrix metalloproteinase inhibitorsFarnesyl transferase inhibitorsIntensive chemotherapyConditioning regimensSupportive careFavorable cytogeneticsPrognostic factorsAntimetabolite therapyMarrow transplantationMDS patientsTreatment paradigmClinical trialsProtein kinase C inhibitorMycosis fungoides and the Sézary syndrome
Foss F. Mycosis fungoides and the Sézary syndrome. Current Opinion In Oncology 2004, 16: 421-428. PMID: 15314509, DOI: 10.1097/00001622-200409000-00002.Peer-Reviewed Original ResearchConceptsEarly-stage patientsSézary syndromeMycosis fungoidesTreatment paradigmPeptide-loaded dendritic cellsEvolution of immunotherapyUse of photopheresisClinical prognostic factorsNucleoside analogue therapyReceptor-directed therapyT cell responsesTreatment of patientsNon-Hodgkin lymphomaNovel treatment optionsFurther clinical evaluationNovel therapeutic approachesHistone deacetylase inhibitorsWorld Health OrganizationAnalogue therapySystemic therapyClinical stagingDendritic cellsPrognostic factorsSézary cellsClinical entity